A5018601955- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- Bone health and treatments
- Biochemical and Molecular Research
- Protein Kinase Regulation and GTPase Signaling
- Ubiquitin and proteasome pathways
- Signaling Pathways in Disease
- Zebrafish Biomedical Research Applications
- Immunotherapy and Immune Responses
- Erythrocyte Function and Pathophysiology
- Autophagy in Disease and Therapy
- Endoplasmic Reticulum Stress and Disease
- PI3K/AKT/mTOR signaling in cancer
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
University of Padua
2019-2023
Veneto Institute of Molecular Medicine
2019-2023
Multiple myeloma (MM) is a tumor of plasma cells (PCs). Due to the intense immunoglobulin secretion, PCs are prone endoplasmic reticulum stress and activate several stress-managing pathways, including autophagy. Indeed, autophagy deregulation maladaptive for MM cells, resulting in cell death. CK1α, pro-survival kinase MM, has recently been involved as regulator autophagic flux transcriptional competence autophagy-related transcription factor FOXO3a cancers. In this study, we investigated...
Multiple myeloma (MM) is a malignant plasma cell (PC) neoplasm, which also displays pathological bone involvement. Clonal expansion of MM cells in the marrow causes perturbation homeostasis that culminates MM-associated disease (MMABD). We previously demonstrated S/T kinase CK1α sustains survival through activation AKT and β-catenin signaling. negative regulator Wnt/β-catenin cascade, promotes osteogenesis by directly stimulating expression RUNX2, master gene osteoblastogenesis. In this...
Mantle cell lymphoma (MCL) is an incurable B non-Hodgkin lymphoma, characterized by frequent relapses. In the last decade, pro-survival pathways related to BCR signaling and Bcl-2 have been considered rational therapeutic targets in derived lymphomas. The BTK inhibitor Ibrutinib Venetoclax are emerging as effective drugs for MCL. However, primary acquired resistance also these agents may occur. Protein Kinase CK2 a S/T kinase overexpressed many solid blood-derived tumours. promotes cancer...
The Ser-Thr kinase CK2 plays important roles in sustaining cell survival and resistance to stress these functions are exploited by different types of blood tumors. Yet, the physiological involvement normal development is poorly known. Here, we discovered that β regulatory subunit critical for hematopoiesis mouse. Fetal livers conditional CK2β knockout embryos showed increased numbers hematopoietic stem cells associated a higher proliferation rate compared control animals. Both progenitor...
The biology of plasma cell dyscrasias (PCD) involves both genetic and immune-related factors. Since lesions are necessary but not sufficient for Multiple Myeloma (MM) evolution, several authors hypothesized that immune dysfunction involving B T counterparts plays a key role in the pathogenesis disease. aim this study is to evaluate impact cornerstone treatments into system shaping. A large series 976 bone marrow samples from 735 patients affected by PCD was studied flow analysis identify...
Mantle Cell Lymphoma (MCL) is still an incurable B-cell malignancy characterized by poor prognosis and frequent relapses. B Receptor (BCR) signaling inhibitors, in particular of the kinases BTK PI3Kγ/δ, have demonstrated clinically meaningful anti-proliferative effects cell tumors. However, refractoriness to these drugs may develop, portending a dismal prognosis. Protein kinase CK1α emerging pro-growth enzyme malignancies. In multiple myeloma, this sustains β-catenin AKT-dependent survival...
Background: Mantle Cell lymphoma (MCL) is a B‐cell malignancy comprising roughly 5–10% of B non Hodgkin lymphomas. MCL patients have been demonstrated to be particularly sensitive the Bruton Tyrosin kinase (BTK) inhibitor ibrutinib, which by impinging on Receptor (BCR)‐associated signalling events, causes neoplastic cell apoptosis and proliferation arrest. Nevertheless, refractoriness ibrutinib may develop portending dismal prognosis, thus for such cases novel therapeutic strategies are...
Background: Mantle cell lymphoma (MCL) is a B-cell tumor which often relapses. BCR inhibitors (Ibrutinib, Acalabrutinib) and antiapoptotic BCL2-family members blockers BH3-mimetics (Venetoclax, ABT-199) are effective drugs to fight MCL. However, the disease remains incurable, due therapy resistance, even promising Venetoclax Ibrutinib combination. Therefore, there profound need explore novel useful therapeutic targets. CK2 S/T kinase overexpressed in several solid blood tumors. We...